Develops immunotherapy treatments targeting specific proteins to combat solid tumors and overcome cancer treatment resistance.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Overview
Catalym is a biopharmaceutical company that focuses on developing immunotherapies for solid tumors by targeting GDF-15, a protein implicated in resistance to cancer treatments. Its lead candidate, visugromab, is a monoclonal antibody designed to neutralize GDF-15, aiming to restore effective anti-tumor immune responses.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Catalym Management Team
Catalym Valuations & Financials
View real-time NPM data on Catalym stock including daily Catalym stock price estimates, valuation history, and historical share price information. Access Catalym financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track Catalym pricing across six independent market signals. Looking for private company due diligence data sources on Catalym? Get in touch to learn more.
Similar Companies
like Catalym
Iris Telehealth
Healthcare & Life Sciences
Telepsychiatry services for community mental health systems.
Trusted
Healthcare & Life Sciences
Digital employment platform built by nurses for nurses.
Nutcracker Therapeutics
Healthcare & Life Sciences
Develops RNA-based therapeutics using innovative manufacturing and synthesis platform to advance mRNA treatments and formulations.
Rightway
Healthcare & Life Sciences
Guides members to optimal care and medications with personalized navigation and transparent pharmacy benefit solutions.
Brightseed
Healthcare & Life Sciences
Discovers plant-based bioactive compounds to enhance health, providing sustainable solutions for food, beverage, and wellness.
Tempus Labs
Healthcare & Life Sciences
Utilizes AI-driven data integration to deliver personalized medical insights.
FAQ
We have answers
Catalym stock does not trade on public stock exchanges. Catalym stock is considered a private security and you need to be an accredited investor to trade shares. To invest in Catalym stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
Catalym Stock does not trade on public stock exchanges. In order to sell Catalym shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
Catalym does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view Catalym share price and other valuable private market data.
Read more about secondary market private company stock prices:
There is no ticker symbol for Catalym stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell Catalym stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in Catalym stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
Catalym is a private company and has not had an IPO. There is currently no Catalym IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to Catalym IPO.
Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.
